Tri-Luma Cream Available Again

Galderma Laboratories, L.P. recently announced that Tri-Luma® (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) Cream, the only FDA-approved triple combination topical product indicated for the short-term (up to 8 weeks) treatment of moderate to severe melasma of the face, is now available again in pharmacies nationwide. Tri-Luma® Cream contains a clinically-proven formula which combines three active ingredients: fluocinolone acetonide 0.01%, a mild corticosteroid that reduces inflammation; hydroquinone 4%, a de-pigmenting agent that interrupts the formation and synthesis of melanin to help lighten the skin; and tretinoin 0.05%, which works to increase the skin cell turnover rate to exfoliate skin. Currently there is no generic equivalent.